Matt Gline

CEO @Roivant, improving the delivery of healthcare to patients by treating every inefficiency as an opportunity

[BiotechTV @BiotechTV]

𝐎𝐟𝐟-𝐓𝐚𝐫𝐠𝐞𝐭 𝐄𝐟𝐟𝐞𝐜𝐭𝐬: @BridgeBioPharma Founder & CEO Neil Kumar and @Roivant CEO @gline discusses the hub and spoke biotech model and trying to build a sustainable business for the long-term. $BBIO $ROIV

Watch the full episode: https://t.co/LQLglZ4EKP

[Matt Gline @gline]

@MattZeitlin You’ll get silly answers but the boring truth is running a trial is a coordination problem among hundreds of doctors, patients, and staff. AI will read charts, draft and help negotiate agreements, and manage a boatload of email traffic, same as with any other business problem.

[Matt Gline @gline]

This was a great conversation! Thanks @JMaraganore!

[BiotechTV @BiotechTV]

𝐎𝐟𝐟-𝐓𝐚𝐫𝐠𝐞𝐭 𝐄𝐟𝐟𝐞𝐜𝐭𝐬: @JMaraganore has been a champion of innovation throughout his career. He and @gline discuss the road to success at @Alnylam, today's environment, and keeping the U.S. on top.

Watch the episode: https://t.co/AtVmcj7Tou

[Matt Gline @gline]

Congrats @bradloncar!

[Brad Loncar @bradloncar]

Tomorrow is the two year anniversary of the launch of BiotechTV. That the industry’s top leaders recognize how it has grown in relevance and reach over this time is an awesome thing.

[Matt Gline @gline]

@bradloncar I am 1000% supportive of this idea.

[Matt Gline @gline]

This was a fun one, @adamfeuerstein!

[BiotechTV @BiotechTV]

𝐎𝐟𝐟-𝐓𝐚𝐫𝐠𝐞𝐭 𝐄𝐟𝐟𝐞𝐜𝐭𝐬 𝐰𝐢𝐭𝐡 𝐌𝐚𝐭𝐭 𝐆𝐥𝐢𝐧𝐞: @gline speaks with @statnews' @adamfeuerstein about the dynamics of biotech journalism and how it compares to other industries.

Full video: https://t.co/pVh6r5utkf

[Matt Gline @gline]

This was a fun conversation! Thanks Behzad, @bradloncar and @BiotechTVHQ

[BiotechTV @BiotechTV]

𝐎𝐟𝐟-𝐓𝐚𝐫𝐠𝐞𝐭 𝐄𝐟𝐟𝐞𝐜𝐭𝐬: @gline speaks with Avoro Capital's Behzad Aghazadeh about the hot button issues that have been striking the biotech sector.

Full video: https://t.co/U5lO5ZtTTg

[BiotechTV @BiotechTV]

𝐓𝐨𝐦𝐨𝐫𝐫𝐨𝐰: Tune in tomorrow for a new episode of Off-Target Effects with @gline. Matt interviews Avoro Capital's Behzad Aghazadeh.

[Matt Gline @gline]

@given2tweet This is totally fair! We didn't think of it but will do next time.

[Matt Gline @gline]

@given2tweet I probably could have taken that one, actually...

[Matt Gline @gline]

@given2tweet @70 I can give German Merck a call…

[Matt Gline @gline]

@Biohazard3737 Anything, including appearing on "Queer Eye" per this recommendation from @BaniaInvestor, is on the table if we think it would help.

[Matt Gline @gline]

@adar170 @biotech_bro As far as I know he still has a lot of other things on his plate.

[Matt Gline @gline]

@BiotechCH Thanks for the battlefield promotion!

[Matt Gline @gline]

@Biohazard3737 Should we? I think we have to take the risks we are best at assessing, but I have occasionally had (slightly depressing) visions of how much easier in terms of time and tears putting it all in BTC (or NVIDIA stock, or bored apes, etc) might have been.

[Matt Gline @gline]

@AcidsmanL @john_bresnahan @PharmaVoice Hey, we fail all the time without even trying! It’s just a fact of life in biotech…

[Matt Gline @gline]

@short_vix Yes

[Matt Gline @gline]

@given2tweet My first instinct in thinking this through is you should definitely get some better CEOs to follow you, you are scraping the bottom of the barrel!

[Matt Gline @gline]

@given2tweet @trygln88 Don’t know yet! But weird markets and good data trump weird data and good markets every day of the week…